SAN FRANCISCO – The capital markets were already ugly heading into the 34th J.P. Morgan Healthcare conference (JPM) and they got even worse by the day as biopharma companies strutted their stuff for four intense days of presentations. Although the overall message that resulted from the event is that the industry is alive and well with strong fundamentals, it didn't translate into a positive performance on the markets until the final day of the meeting.